Tapping into thinking through mobile apps in schizophrenia

Not yet recruiting

Conditions: Schizophrenia,

Registration Number: CTRI/2023/08/056708

Lead Sponsor: Beth Israel Deaconess Medical Center (BIDMC)

Brief Summary: In the current study we propose to address challenges around the assessment of cognition as well as its measurement in the context of different environments and circadian terms through a novel concept called micro cognitive and contextual momentary performance. Micro cognitive and contextual momentary performance metrics involve two core elements captured simultaneously: 1) brief self- administered scalable smartphone measures of cognitive performance; and 2) digital phenotyping measures of symptoms, activity levels, sleep patterns, and related functional / environmental factors. These related functional / environmental factors include metrics about the immediate environment (light, ambient sound levels, social density) and personal state (sleep, mobility, and activity metrics). These micro cognitive and contextual momentary performance metrics are designed to be offered multiple times per day via a smartphone and thus represent a scalable means to bring novel cognitive performance measurement into the hands of millions of people with schizophrenia. In this study, we will co-develop a battery of these assessments designed to measure those cognitive domains most impacted in early course schizophrenia, refine that battery in pilot testing, and finally assess the potential of our micro cognitive and contextual momentary performance metrics against functional outcomes with personalized scoring controlling for differing environments and circadian rhythms. Our goal is to introduce accessible micro cognitive and contextual momentary performance metrics and study their utility in assessing real world functioning and symptoms in first episode schizophrenia.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 102

Inclusion Criteria

1.Diagnosis of a psychotic disorder 2.Severity of symptoms at least to a mild degree on The Positive and Negative Syndrome Scale (PANSS) over the past 3 months 3.If prescribed, a stable medication dosage for at least the past month (self-report and clinical records).

Exclusion Criteria

1.Substance use disorder during the last 3 months 2.Benzodiazepines in the last 4 weeks.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess changes in micro cognitive & contextual momentary performance metrics as correlated to changes in functioning, positive symptoms of schizophrenia, and any changes in the MATRICS Consensus Cognitive Battery (MCCB)	0,90,and180days

Secondary Outcome Measures

Name	Time	Method
To assess changes in micro cognitive & contextual momentary performance in relation to functioning and psychotic-like experiences	0,90,and180days

Trial Locations

Locations (3): All India Institute of Medical Sciences (AIIMS)
🇮🇳
Bhopal, MADHYA PRADESH, India
National Institute of Mental health and Neurosciences
🇮🇳
Bangalore, KARNATAKA, India
Sangath
🇮🇳
Bhopal, MADHYA PRADESH, India
All India Institute of Medical Sciences (AIIMS)
🇮🇳Bhopal, MADHYA PRADESH, India
Dr Abhijit R Rozatkar
Principal investigator
07552835096
abhijit.psy@aiimsbhopal.edu.in